Blood test may spot ovarian cancer return before symptoms show

NCT ID NCT06588322

Recruiting now Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test can find genetic changes in tumor DNA that signal ovarian cancer is coming back. It involves 130 women with BRCA mutations who are taking a maintenance drug called Olaparib after initial treatment. The goal is to see if these blood tests can detect cancer progression earlier than standard scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Chu de Limoges
RECRUITING

Limoges, France
Chu de Nimes
RECRUITING

Nîmes, France
INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Angers
RECRUITING

Angers, France
INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Saint-Herblain
RECRUITING

Saint-Herblain, France
IUCT-O
RECRUITING

Toulouse, France
Institut Bergonie
RECRUITING

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.